Tyrosine kinase inhibitor discontinuation in non-allografted Philadelphia-positive acute lymphoblastic leukemia patients: a Campus ALL real-life study
Not available.
Saved in:
| Main Authors: | Matteo Dragani, Michela Ansuinelli, Cristina Papayannidis, Nicola Fracchiolla, Valeria Cardinali, Michele Cedrone, Fabio Guolo, Salvatore Perrone, Prassede Salutari, Elisabetta Todisco, Robin Foà, Sabina Chiaretti |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-01-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11897 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia
by: Xiaoxia Wu, et al.
Published: (2024-09-01) -
Reduced-intensity chemotherapy with tyrosine kinase inhibitor followed by allogeneic transplantation is effective in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
by: Jung Min Lee, et al.
Published: (2025-01-01) -
Tyrosine Kinase Inhibitor Post-Allogeneic Stem Cell Transplantation in Adult Philadelphia-Positive B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions
by: Martina Canichella, et al.
Published: (2025-02-01) -
Relapsed Philadelphia chromosome‐positive B‐cell acute lymphoblastic leukaemia responds well to a combination of modified hyper‐CVAD, blinatumomab and tyrosine kinase inhibitor
by: Gaétan Basile, et al.
Published: (2025-02-01) -
Relapse after Prolonged Remission in Philadelphia-Like Acute Lymphoblastic Leukemia
by: Gaurav Shah, et al.
Published: (2019-01-01)